Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECTMe: Melatonin for Neuroprotection in Fetal Growth Restriction
NCT05651347Phase 3Recruiting
- Sponsor
- Monash University
- Start
- May 2019
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, triple-blind trial in fetal growth restriction (FGR) comparing Melatonin with Placebo (2 arms). Primary endpoint: Neurodevelopmental performance at 2 years of life. Started May 2019; status: recruiting.
02
Drugs
melatonin
03
Conditions
fetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT05651347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651347.